Lyumjev

Lyumjev is a brand of insulin used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. It is a rapid-acting insulin analog marketed by Eli Lilly and Company. Lyumjev is a formulation of insulin lispro, which is designed to act more quickly than regular insulin lispro formulations such as Humalog.

Medical uses

Lyumjev is used to improve blood sugar control in adults with diabetes mellitus. It is typically administered via subcutaneous injection and is used primarily at meal times to manage blood glucose levels.

Mechanism of action

Lyumjev works by accelerating the absorption of insulin through the addition of ingredients that increase blood flow at the injection site. This rapid-acting insulin begins to work within minutes of injection, which helps to mimic the natural release of insulin that occurs in people without diabetes, particularly right after meals.

Development and Approval

Lyumjev was developed by Eli Lilly and Company as an improved version of their earlier product, Humalog, with the goal of providing faster action and better mimicry of natural insulin release. It was approved by regulatory bodies such as the Food and Drug Administration (FDA) for use in the United States.

Side Effects

Like other insulin products, Lyumjev can cause side effects, including hypoglycemia (low blood sugar levels), allergic reactions, injection site reactions, and lipodystrophy (abnormal distribution of body fat). Proper dosing and monitoring are essential to minimize these risks.

See Also

• Insulin therapy
• Diabetes management

‎